FGFR2 and cholangiocarcinoma: In a phase I dose expansion cohort of FGFR2 translocated cholangiocarcinoma receiving erdafinitib (n = 11), objective responses were observed in 3 patients (27.3%) with an additional 3 patients achieving stable disease[35].